Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO ...

Genentech, part of the Roche Group (OTCQX:RHHBY), said that a late-stage study testing Lunsumio, along with Polivy, showed ...

In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor burden follicular ...

How Does Lunsumio Work for FL? Lunsumio is a special type of molecule that can attach to two different types of cells. This is called a bispecific antibody. It attaches to CD20 proteins on ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved Lunsumio ® (mosunetuzumab ...

The other candidate is known as Lunsumio [mosunetuzumab] has been approved for the treatment of patients with 3rd-line FL. In the most recent Q1 of 2025 earnings report, it was revealed that both ...

Morningstar brands and products Company Portfolio ...

The FDA has granted a priority review to Roche's T-cell engager Lunsumio as a treatment for follicular lymphoma (FL), setting up a decision on the drug by 29 December. The first-in-class drug ...

Chugai Pharmaceutical Co., Ltd., a subsidiary of Roche, announced that it launched “Lunsumio for intravenous infusion 1 mg” and “Lunsumio for intravenous infusion 30 mg” (generic name: mosunetuzumab ...

Data showcase the benefits of fixed-duration Columvi (glofitamab-gxbm) and Lunsumio (mosunetuzumab-axgb) across different types of aggressive and indolent lymphomas. The company noted that long ...

Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than ...

(2024-12-09 | OTCQX:RHHBY) New and Updated Data for Genentech's Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma Stockhouse.com ...